Skip to main content
. Author manuscript; available in PMC: 2019 Aug 7.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2014 Aug 14;34(10):2349–2357. doi: 10.1161/ATVBAHA.114.303784

Table 4.

Multivariate General Linear Model ANOVA Analyzing the Relationship Between Soluble Receptor for Advanced Glycation End Product Level and Study Variables in 66 Patients With BAV and TAV With AA Diameter <4.5 cm

Factors in the Model Df F-Statistic P Value
Covariates
 Age, y   1     0.249  0.620
 AA diameter   1     3.526  0.066
 Body surface area   1     3.879  0.055
 Combined covariates   3     2.817 0.049*
Main effects
 BAV vs TAV group   1* 7.750* 0.008*
 AVS   3     0.527  0.666
 Sex   1     1.156  0.288
 Coronary artery disease   1     0.451  0.505
 Diabetes mellitus   1     0.004  0.947
 Smoking   1     2.125  0.151
 Hyperlipidemia   1     0.386  0.537
 Hypertension   1     0.810  0.372
 AVI   3     0.593  0.623
 Combined model 16     2.307 0.013*

AA indicates ascending aortic diameter; AVI, aortic valve insufficiency; AVS, aortic valve stenosis; BAV, bicuspid aortic valve; and TAV, tricuspid aortic valve.

*

indicates significance.